Fig. 6.

U0126 treatment inhibits activation of the Wnt-1/β-catenin signaling pathway in kidney of hyperuricemic rats. HN, hyperuricemic nephropathy. A: kidney tissue lysates were subjected to immunoblot analysis with specific antibodies against Wnt1, β-catenin, and GAPDH. B: expression level of Wnt1 was quantified by densitometry and normalized to GAPDH. C: expression level of β-catenin was quantified by densitometry and normalized to GAPDH. Data are presented as means ± SE (n = 6). Means with different superscript letters are significantly different from one another (P < 0.05).